Nomura Y, Tominaga T, Adachi I, Koyama H, Fukami A
Dept. of Breast Surgery, National Kyushu Cancer Center.
Gan To Kagaku Ryoho. 1994 Sep;21(12):1949-56.
The clinical efficacy of "CMF" chemotherapy, (cyclophosphamide, methotrexate, 5-fluorouracil), was evaluated on advanced and recurrent breast cancer. The response rate was 36.1% in 61 evaluable cases, including four CR and eighteen PR. In terms of efficacy classified by metastatic lesion, the effective rates were 51.4% in soft tissue, 28.6% in viscera, and 20.0% in bone metastases. The main side effects were nausea/vomiting, anorexia, and leucopenia. In this study, CMF chemotherapy resulted in good clinical effects, and its response rate was almost the same as that to CMF chemotherapy in Europe and USA, but slightly lower than that to CAF chemotherapy. As to the side effects, the incidence of leucopenia, thrombocytopenia or alopecia was lower in CMF chemotherapy than in CAF chemotherapy. Also, unlike CAF chemotherapy, CMF chemotherapy had no cumulative dose-limitation and showed no cardiotoxicity. In conclusion, CMF chemotherapy is considered to be one of the most useful treatments for advanced and recurrent breast cancer.
评估了“CMF”化疗方案（环磷酰胺、甲氨蝶呤、5-氟尿嘧啶）对晚期及复发性乳腺癌的临床疗效。在61例可评估病例中，缓解率为36.1%，包括4例完全缓解（CR）和18例部分缓解（PR）。按转移病灶分类的疗效方面，软组织转移的有效率为51.4%，内脏转移为28.6%，骨转移为20.0%。主要副作用为恶心/呕吐、厌食和白细胞减少。本研究中，CMF化疗产生了良好的临床效果，其缓解率与欧美地区CMF化疗的缓解率相近，但略低于CAF化疗。至于副作用，CMF化疗中白细胞减少、血小板减少或脱发的发生率低于CAF化疗。此外，与CAF化疗不同，CMF化疗没有累积剂量限制，也未表现出心脏毒性。总之，CMF化疗被认为是晚期及复发性乳腺癌最有效的治疗方法之一。
